Judicial Watch on July 26 obtained 112 pages of documents from the U.S. Food and Drug Administration (FDA) revealing top officials at the agency were being pressured to conform to the Biden Administration’s timeline for COVID-19 vaccine boosters. The records were disclosed as part of a Freedom of Information Act (FOIA) lawsuit filed against the […]
Moderna
FDA Colluded with Moderna to Bypass COVID Vaccine Regulatory and Safety Standards, Documents Show
According to an ex-pharmaceutical industry and biotech executive, documents obtained from the U.S. Department of Health and Human Services (HHS) on Moderna’s COVID-19 vaccine suggest the U.S. Food and Drug Administration (FDA) and Moderna colluded to bypass regulatory and scientific standards used to ensure products are safe. Alexandra Latypova has spent 25 years in pharmaceutical […]
Biden Admin Signed $3.2 Billion Pfizer Deal Before FDA Decided How Boosters Should be Reformulated
The U.S. Food and Drug Administration (FDA) advised COVID-19 vaccine manufacturers on June 30 that any modifications to booster shots for fall will need to target Omicron subvariants BA.4 and BA.5, which account for more than half of new virus cases in the U.S. Original vaccines based on the Wuhan strain that is no longer circulating will be used for anyone […]
New Study Questions Safety of mRNA COVID-19 Vaccines
A new scientific study entitled “Serious adverse events of special interest following mRNA vaccination in randomized trials” provides the best evidence yet concerning the safety of the mRNA Covid vaccines. For most vaccines in common use, benefits far outweigh risks, but that may not be the case for the mRNA covid vaccines, according to this study by […]
FDA Panel Sets Dangerous Precedent by Recommending New COVID Boosters Without Data
The U.S. Food and Drug Administration’s (FDA) vaccine advisory panel on Tuesday voted 19 to 2 to recommend new COVID-19 booster shots that include the Omicron variant this fall. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) did not issue guidance on whether additional data, if any, would be needed to recommend an […]